NDAINHALATIONAEROSOL, METERED
Approved
Aug 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
AEROBID (flunisolide) by Roche is clinical pharmacology flunisolide has demonstrated potent glucocorticoid and weak mineralocorticoid activity in classical animal test systems. Approved for asthma, allergic rhinitis. First approved in 1984.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AEROBID (flunisolide) is an inhaled corticosteroid that acts as a potent glucocorticoid with local anti-inflammatory effects on nasal and bronchial mucous membranes. It is indicated for asthma, allergic rhinitis, and distal lung inflammation, with therapeutic activity primarily driven by direct local effect rather than systemic absorption. Flunisolide undergoes rapid first-pass hepatic metabolism, minimizing systemic exposure at recommended doses.
LOE Approaching
LOE-approaching lifecycle indicates shrinking team resources; expect consolidation or transition roles in commercial organization.
Mechanism of Action
CLINICAL PHARMACOLOGY Flunisolide has demonstrated potent glucocorticoid and weak mineralocorticoid activity in classical animal test systems. As a glucocorticoid, it is several hundred times more potent than the cortisol standard. Clinical studies with flunisolide have shown therapeutic activity…
Worked on AEROBID at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.